Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05106335
Other study ID # SHR-1210-III-332
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date January 6, 2022
Est. completion date May 11, 2022

Study information

Verified date August 2023
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date May 11, 2022
Est. primary completion date May 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer. 2. Failed previous platinum-based chemotherapy and anti-PD-(L)1 monoclonal antibody treatment. 3. Have measurable disease based on RECIST v1.1. 4. ECOG PS score: 0-1. 5. Expected survival = 3 months. 6. Non-surgically sterilized female subjects or women of childbearing potential must be negative for a serum pregnancy test within 3 days prior to the first dose and must be non-lactating. Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to take highly effective contraceptive measures during the study period and until 6 months after the last study dose. 7. Subjects must participate voluntarily, sign the ICF, have good compliance, and cooperate with follow-up visits. Exclusion Criteria: 1. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites. 2. Have known history of prior malignancy in the past 3 years. 3. Have active pulmonary tuberculosis. 4. Have clinical symptoms of the heart or heart diseases that are not well controlled. 5. Have hypertension which cannot be well controlled by antihypertensives 6. Urinalysis has indicated that the urine protein is = ++ and quantitative test of urine protein has confirmed that the 24-h urine protein is > 1.0 g. 7. Have a thrombosis tendency or are currently receiving thrombolysis/anticoagulation therapy. 8. Have received major surgery within 4 weeks prior to randomization; or palliative radiotherapy within 2 weeks prior to randomization; or have not recovered from the toxicities and/or complications of previous interventions to NCI-CTCAE Grade = 1. 9. Have known history of arterial/venous thrombosis within 6 months prior to randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism. 10. Are currently participating and receiving study therapy or have participated in a study and received the last dose of study drug within 4 weeks (or 5 half-lives of the study drug) prior to randomization. 11. Previous treatment with camrelizumab, docetaxel, and small-molecule VEGFR inhibitors including famitinib. 12. Have other potential factors that may affect the study results or result in the premature discontinuation as determined by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
camrelizumab + famitinib
camrelizumab for intravenous injection; famitinib malate capsules for oral administration
famitinib
famitinib malate capsules for oral administration
docetaxel
docetaxel for intravenous injection

Locations

Country Name City State
China Subei People's Hospital of Jiangsu Province Yangzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary OS OS is the time interval from the date of randomization to death due to any reason or lost of follow-up. up to 4 years
Secondary PFS Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression with use of RECIST v1.1 or death from any cause, whichever occurs first. up to 4 years
Secondary ORR Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points. up to 4 years
Secondary DoR Duration of Response, determined using RECIST v1.1 criteria. up to 4 years
Secondary DCR Disease Control Rate, determined using RECIST v1.1 criteria. up to 4 years
Secondary TTF Time to Treatment Failure, defined as the time from randomization to treatment discontinuation. up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00813332 - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase 4
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Not yet recruiting NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Phase 4
Completed NCT03074175 - Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer:Multicenter Controlled Study.(RadmiR-01) N/A
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A
Active, not recruiting NCT04043195 - Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Phase 1/Phase 2